IL261340B2 - The composition for the treatment of cancer or a skin lesion - Google Patents

The composition for the treatment of cancer or a skin lesion

Info

Publication number
IL261340B2
IL261340B2 IL261340A IL26134018A IL261340B2 IL 261340 B2 IL261340 B2 IL 261340B2 IL 261340 A IL261340 A IL 261340A IL 26134018 A IL26134018 A IL 26134018A IL 261340 B2 IL261340 B2 IL 261340B2
Authority
IL
Israel
Prior art keywords
hpv
vaccine
dose
cancer
composition
Prior art date
Application number
IL261340A
Other languages
English (en)
Hebrew (he)
Other versions
IL261340B1 (en
IL261340A (en
Inventor
Loannides Tim
Original Assignee
Hpvvax Llc
Loannides Tim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax Llc, Loannides Tim filed Critical Hpvvax Llc
Publication of IL261340A publication Critical patent/IL261340A/en
Publication of IL261340B1 publication Critical patent/IL261340B1/en
Publication of IL261340B2 publication Critical patent/IL261340B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL261340A 2016-02-27 2018-08-23 The composition for the treatment of cancer or a skin lesion IL261340B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (3)

Publication Number Publication Date
IL261340A IL261340A (en) 2018-11-29
IL261340B1 IL261340B1 (en) 2023-03-01
IL261340B2 true IL261340B2 (en) 2023-07-01

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
IL261340A IL261340B2 (en) 2016-02-27 2018-08-23 The composition for the treatment of cancer or a skin lesion

Country Status (16)

Country Link
EP (1) EP3419661A4 (cg-RX-API-DMAC10.html)
JP (3) JP2019506435A (cg-RX-API-DMAC10.html)
KR (1) KR102873848B1 (cg-RX-API-DMAC10.html)
CN (2) CN122399006A (cg-RX-API-DMAC10.html)
AU (1) AU2017223970B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018067550A2 (cg-RX-API-DMAC10.html)
CA (1) CA3015519A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018002438A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018009205A2 (cg-RX-API-DMAC10.html)
HK (1) HK1256935A1 (cg-RX-API-DMAC10.html)
IL (1) IL261340B2 (cg-RX-API-DMAC10.html)
MX (1) MX2018010338A (cg-RX-API-DMAC10.html)
MY (1) MY194694A (cg-RX-API-DMAC10.html)
SG (1) SG11201807080UA (cg-RX-API-DMAC10.html)
WO (1) WO2017147475A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201805679B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
ES2962700T1 (es) * 2020-10-12 2024-03-20 Hpvvax Llc Composición y método para tratar el cáncer, usando una vacuna como un primer ingrediente activo terapéutico en combinación con un segundo ingrediente activo
CN120302980A (zh) * 2022-10-31 2025-07-11 皮洛杰斯股份有限公司 免疫疗法组合物和使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
AR074485A1 (es) 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
CN104203270A (zh) * 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
US20130251782A1 (en) 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3054994A4 (en) * 2013-10-13 2017-10-11 The Board of Trustees of the University of Arkansas Human papilloma virus therapeutic vaccine
WO2015106281A1 (en) * 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA2965498A1 (en) * 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof

Also Published As

Publication number Publication date
IL261340B1 (en) 2023-03-01
AU2017223970A1 (en) 2018-09-13
IL261340A (en) 2018-11-29
KR102873848B1 (ko) 2025-10-17
MX2018010338A (es) 2018-11-09
JP2019506435A (ja) 2019-03-07
CN108883168A (zh) 2018-11-23
EP3419661A4 (en) 2019-10-23
AU2017223970B2 (en) 2022-01-27
CO2018009205A2 (es) 2018-09-20
EP3419661A1 (en) 2019-01-02
MY194694A (en) 2022-12-15
KR20180112043A (ko) 2018-10-11
CN122399006A (zh) 2026-07-17
JP7732784B2 (ja) 2025-09-02
ZA201805679B (en) 2019-11-27
BR112018067550A2 (pt) 2019-10-01
CA3015519A1 (en) 2017-08-31
CL2018002438A1 (es) 2019-01-04
JP2021155448A (ja) 2021-10-07
HK1256935A1 (zh) 2019-10-04
JP2023110038A (ja) 2023-08-08
SG11201807080UA (en) 2018-09-27
WO2017147475A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
JP2002525331A (ja) 神経根障害を処置するための所定薬剤の使用
JP7732784B2 (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
CN109562281A (zh) 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
WO2009155777A1 (zh) 法舒地尔化合物的用途、方法及其药物组合物
US20060148712A1 (en) Monocyte chemoattractant activity of galectin-3
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
CN116115760A (zh) Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
US20210393549A1 (en) New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations
US10799574B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
AU2021360676B2 (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
WO2023150767A1 (en) Methods of weight loss and preserving skeletal muscle mass
IL297852A (en) E protein channel blockers, and orf3 inhibitors, against covid 19
CN118948873B (zh) 金线莲苷在防治脑胶质瘤中的应用
US20250345312A1 (en) Formulation and method for treatment of alzheimer's disease, stroke and diabetic retinopathy
KR20180129919A (ko) 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита
KR20250127153A (ko) 약물 조합 및 이의 용도
KR20230051091A (ko) 에제티미브를 유효성분으로 포함하는 폐섬유증의 예방, 개선, 완화 또는 치료용 약학적 조성물
AU2023214495A1 (en) Methods of weight loss in a subject with elevated hba1c
CN120960217A (zh) Ca-170在制备治疗多房棘球蚴病药物中的应用